| Name | Title | Contact Details |
|---|
Mvp Laboratories is a Omaha, NE-based company in the Business Services sector.
PCHonlinenetwork is a Port Washington, NY-based company in the Business Services sector.
Marathon Pharmaceuticals is dedicated to improving the lives of patients with few or no treatment options by delivering new medicines for rare diseases and keeping small volume, hard-to-manufacture medications available for people who need them. There are more than 6,000 recognized rare diseases for which no treatment exists. Many pharmaceutical companies are unwilling or unable to invest in treatments for diseases that affect fewer than 200,000 patients. Marathon is different.Marathon was founded to tackle the toughest challenge in medicine: developing treatments for the most complex rare diseases. All corporate profits are reinvested to build our pipeline of promising rare disease treatments. As a privately held company, Marathon can devote its resources to developing new therapies that might not otherwise reach patients. Marathon’s branded prescription medicines are used to treat a variety of conditions. We work to ensure that these important medicines are available for those who need them by investing heavily in high quality manufacturing and a reliable supply chain.
Situs Judi Slot Online Joker123 Terpercaya bet kecil gampang menang di CERIABET. Melayani Daftar Judi Online24jam Khusus deposit murah 10rb
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.